Rezolute Inc.

News & Events

Press Releases

In The Media

1. Rezolute Announces Completion of Enrollment in the Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism

   GlobeNewswire MAY 28, 2025 8:00 AM EDT
   Target enrollment exceeded with 62 participants enrolled, including approximately 15 percent from...
   READ ARTICLE

2. Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update

   GlobeNewswire MAY 13, 2025 4:05 PM EDT
   sunRIZE enrollment on track including U.S. sites and expected to be completed in May 2025; toplin...
   READ ARTICLE

3. Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

   GlobeNewswire MAY 5, 2025 8:00 AM EDT
   Registrational study in patients with tumor hyperinsulinism (HI) expected to commence mid-year ...
   READ ARTICLE

4. Rezolute to Participate in Upcoming Investor Conferences

   GlobeNewswire MAY 1, 2025 8:00 AM EDT
   REDWOOD CITY, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rez...
   READ ARTICLE

5. Rezolute, Inc. Announces Closing of Underwritten Offering

   GlobeNewswire APR 25, 2025 4:30 PM EDT
   NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute ...
   READ ARTICLE

6. Rezolute Announces Pricing of Offering of $90 Million of Common Stock and Pre-Funded Warrants

   GlobeNewswire APR 23, 2025 8:05 AM EDT
   NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute ...
   READ ARTICLE

7. Rezolute Announces Positive Recommendation After Independent Interim Analysis of Phase 3 sunRIZE Study of Ersodetug in Congenital Hyperinsulinism ("HI")

   GlobeNewswire APR 23, 2025 8:00 AM EDT
   Independent Data Monitoring Committee (the “DMC”) recommends continuation of sunRIZ...
   READ ARTICLE

8. Rezolute Announces Appointment of Rare Disease Commercial Leader Erik Harris to its Board of Directors

   GlobeNewswire MAR 26, 2025 7:30 AM EDT
   REDWOOD CITY, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc . (Nasdaq: RZLT), ...
   READ ARTICLE

9. Rezolute Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update

   GlobeNewswire FEB 12, 2025 4:05 PM EST
   Ersodetug, a novel, fully human monoclonal antibody for the treatment of hyperinsulinism (HI), re...
   READ ARTICLE

10. Rezolute Provides Update on its Phase 3 sunRIZE Study of Ersodetug for the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism

    GlobeNewswire FEB 4, 2025 8:00 AM EST
    Open-label arm (infant participants < 1 year old) has been recently reviewed by a Data Monitor...
    READ ARTICLE